Articles Tagged With:
-
Settlement Likely for Missed Diagnosis Case, Even if ED Chart Shows It’s ‘Reasonable’
Defensible cases are settled sometimes because the plaintiff is sympathetic or because the dollar value of damages is high.
-
Did EP Override Safety Prompt for No Apparent Reason? It’s a Hurdle for Defense
Emergency physicians routinely override safety prompts in clinical decision support systems for very good reasons. However, a skilled plaintiff attorney can depict it as a rogue physician’s negligence.
-
ED Staffing Scrutinized if Patient Experiences Bad Outcome in Waiting Room
Plaintiff attorneys allege inadequate ED staffing contributed to patients’ bad outcomes in medical malpractice cases. Typically, accusers allege the hospital allowed dangerously low staffing levels despite concerns and that triage nurses were inadequately trained.
-
The Fourth Amendment: Coming to an ED Near You
ED staff work closely with municipal and state law enforcement officials as well as in-house security workers. That relationship is critical to patient, public, and provider safety. The maintenance of a cordial and functional relationship is imperative. However, it cannot happen at the expense of patients’ health, dignity, and constitutional rights.
-
The Vagaries of Reported Penicillin Allergy
The literature says that > 90% of patients who report a history of penicillin allergy can tolerate penicillin. Unstimulated penicillin sensitivity wanes over time: By age 10 years, 80% of allergic subjects are no longer allergic.
-
Osteoblast Modulation in Osteoporosis Treatment
Most pharmacologic interventions currently in use for treatment or prevention of osteoporosis rely on osteoclast inhibition to enhance (or at least maintain) bone mineral density. In contrast, teriparatide primarily works by stimulation of osteoblasts.
-
Cardiovascular Benefits of Pharmacotherapies for Type 2 Diabetes
The most recent American Diabetes Association 2018 guidance for pharmacotherapy of type 2 diabetes mellitus suggests that for patients with existing cardiovascular (CV) disease who are uncontrolled on metformin and lifestyle, consideration should be given to prioritizing agents demonstrated to provide CV risk reduction (empagliflozin, liraglutide, and canagliflozin).
-
Postprandial Glucose Excursions in Type 2 Diabetes
The most recent American Diabetes Association 2018 guidelines suggest that for persons with established cardiovascular disease who have not attained glucose goals, incorporation of agents that have shown cardiovascular risk reduction (i.e., canagliflozin, empagliflozin, liraglutide) should be a priority.
-
Biomarkers for Tight Control of Crohn’s Disease
The authors suggested that treatment escalation based on the combination of clinical symptoms with biomarkers produces more favorable outcomes.
-
Long-term Outcomes for Obesity
The evidence of the advantages of bariatric surgery over medical management continues to accrue.